SJSamira Jeimy

Samira Jeimy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Samira Jeimy has a total of 203 co-authors. Here are the top co-authors by number of shared publications:

  • Catherine Pauline M. Hayward

    Department of Pathology and Molecular Medicine McMaster University Hamilton Ontario Canada

    6 shared publications
  • Tiffany Wong

    Division of Allergy, Department of Pediatrics, University of British Columbia, Vancouver, Canada

    6 shared publications
  • Rongbo Zhu

    Division of Clinical Immunology and Allergy, Department of Medicine, Western University, London, Ont

    5 shared publications
  • Harold Kim

    McMaster University, Hamilton, Canada

    4 shared publications
  • Nola Fuller

    HSC 2N31, Pathology and Molecular Medicine, McMaster University, 1200 Main St. West, Hamilton, ON, Canada L8N 3Z5 Division of Hematology, Duke University Medical Center, Durham, North Carolina, United States, 27710

    4 shared publications
  • Sabina Vohra-Miller

    Division of Clinical Immunology and Allergy, Department of Medicine, Western University, London, Ontario, Canada

    3 shared publications

Latest Publications

  • Open Access

    Persistent gender pay gaps among Canadian allergists: a population based longitudinal study

    by Samina Nazarali, Xinxin Tang, Zainab Abdurrahman, Donna Plett, Chunga Kim, Sujata Mishra, Tiffany Wong, Victoria E. Cook, Lyn M. Sibley, Samira Jeimy

    Background: Despite growing representation of women in medicine, a persistent gender pay gap remains. In Ontario, women make up over half of Clinical Immunology and Allergy (CIA) physicians, making the field well-suited for examining income disparities. This study uses Ministry of Health data obtained by the Ontario Medical Association to quantify the gender pay gap in CIA and identify contributing factors. Methods: We conducted a longitudinal analysis to investigate the gender pay gap among CIA physicians in Ontario, Canada from 2018 to 2023. Administrative health data, from the Ontario Health Insurance Plan, were analyzed to determine differences in clinical payments by gender. We used multivariable linear mixed-effects models (physician random intercepts) with log-transformed, inflation-adjusted annual clinical income as the outcome and adjusted for physician demographics, practice characteristics, and work patterns. Results: Among 211 CIA physicians in Ontario (2018–2023), mean annual gross clinical payments were higher for male than female physicians ($443,969 vs $279,835; p < 0.001). In adjusted linear mixed-effects models, female physicians earned significantly less than male physicians (β = − 0.25; 95% CI − 0.37 to − 0.13; p < 0.001), corresponding to approximately 22% lower annual clinical income after adjustment for demographic factors, practice characteristics, and work patterns. Interpretation: Our analysis reveals that women physicians earned significantly less than their male counterparts, and the gap persisted even after adjusting for demographic variables, practice characteristics, and work patterns. These findings point to systemic inequities and emphasize the need to address gender-based disparities to support physician retention, satisfaction, and quality of care.

  • Open Access

    Authorship gender diversity in Allergy and Immunology: analysis of articles published in the Canadian journal of Allergy, Asthma & Clinical Immunology

    by Natalie DeGurse, Ranya Al Jumaily, M. Elise Graham, Samira Jeimy

    Background: Gender diversity in authorship enhances the inclusivity and breadth of perspectives in medical research, yet disparities persist across many disciplines, including allergy and immunology. In Canada, women represent the majority of the allergy and immunology workforce, yet it remains unclear whether this is reflected in authorship and academic leadership. Objective: This study examines trends in gender diversity among authors in Allergy, Asthma & Clinical Immunology (AACI), focusing on first, last, and single-author roles, and explores collaborative trends among women authors. Methods: Metadata for AACI articles published from 2011 to 2023 were retrieved using the Web of Science database. Author gender was predicted using the genderize.io tool, supplemented by manual verification for ambiguous cases. Articles with undetermined gender were excluded. Descriptive statistics and logistic regression were employed to identify trends and associations. Results: Of 929 articles, 891 with 5,541 authors were included. Women represented 43.4% of all authors. By role, women comprised 50.8% of first authors, 33.8% of last authors, and 29.4% of single authors. The proportion of women-women first and last author pairs increased significantly from 4.8% in 2011 to 26.9% in 2023 ( p = 0.03). Articles with women as last authors were more likely to feature women as first authors (OR = 1.46, 95% CI: 1.10–1.93, p = 0.009). Conclusion: Although there have been positive trends toward gender parity in AACI authorship, disparities persist, particularly in leadership roles and specific article types. Continued efforts are required to foster equitable representation in allergy and immunology research.

  • Open Access

    Hypersensitivity reactions to iodinated contrast media

    by Samira Jeimy, Zahra Kassam, Ana Maria Copaescu

  • Open Access

    Gender and geographic representation in editorial boards of allergy and immunology journals

    by Ranya Al Jumaily, Natalie DeGurse, M. Elise Graham, Samira Jeimy

    Background: Editorial boards shape academic publishing, yet disparities in gender and geographic representation persist across disciplines. To date, these disparities have not been comprehensively investigated in Allergy and Immunology journals. Objective: To examine gender and geographic representation among editorial board members of Allergy and Immunology journals, highlighting disparities and identifying areas for improvement. Methods: Allergy and Immunology journals were identified using the Clarivate Journal Citation Reports database. Editorial board member data, including names, roles, and locations, were collected from journal websites. Predicted gender was determined using the genderize.io tool. Pearson correlations assessed relationships between journal metrics and editorial board characteristics. Results: A total of 36 journals comprising 1,546 editorial board members were analyzed. Women accounted for 515/1,546 (33.3%) of all editorial board members and were underrepresented in leadership roles. Specifically, only 11/47 (23.4%) of editors-in-chief and 90/244 (36.9%) of deputy/associate editors were women. Geographically, 1,318/1,546 (85.3%) of editorial board members were based in developed countries, with the United States contributing the highest proportion (348/1,546, 22.5%). Women editors constituted 423/1,318 (32.1%) of board members in developed countries and 92/228 (40.4%) in developing countries. Representation of non-binary and transgender identities could not be reliably determined using the available data. Conclusions: Gender and geographic disparities are prevalent in Allergy and Immunology journal editorial boards, with significant underrepresentation of women, particularly in leadership roles, and a concentration of editors in developed countries. Addressing these disparities is essential to fostering inclusivity and equity in academic publishing.

  • Open Access

    Interactive, Personalized Patient Decision Aid for COVID-19 Vaccination in Canada: User-Centered Design Approach

    by Doriane Etienne, Patrick M Archambault, Isaac I Bogoch, Christine T Chambers, Andrea D Chittle, Juliette Demers, S Michelle Driedger, Ève Dubé, Marie-Pierre Gagnon, Teresa Gavaruzzi, et al.

    Background: The COVID-19 pandemic highlighted the need for practical digital health tools to support informed decision-making amid rapidly evolving evidence and widespread misinformation. Objective: We iteratively developed and refined VaxDA-C19, a bilingual (English and French) web-based patient decision aid designed to support informed decision-making in Canada about COVID-19 vaccination. VaxDA-C19 integrates interactive and personalized features aimed to enhance vaccine confidence, reduce cognitive overload, and respond to diverse informational needs. Methods: VaxDA-C19 was developed using an iterative, user-centered design approach. Throughout the development process, we involved a citizen panel, health care professionals, user experience designers, and scientific experts to guide refinements. We also conducted usability testing sessions with adults in Canada, using semistructured interviews, comparative testing, and think-aloud protocols with thematic analysis. We ultimately conducted 4 design cycles in total with adults in Canada (users) and expert reviewers (experts). Cycle 1 involved 9 people (9 users), cycle 2 involved 22 people (22 users), cycle 3 involved 9 people (3 users and 6 experts), and cycle 4 involved 9 people (9 experts). Results: In cycle 1, user feedback guided design decisions about how to present quantitative information and technical vaccine descriptions more simply. In cycle 2, while most users (9/11, 82%) favored in-depth explanations of vaccine development, a few raised concerns about content that could be perceived as politically charged. Cycle 3 identified usability improvements, including more explicit navigation controls, simplified medical terminology, and optimized interactive components (avatars and sliders). Expert reviews in cycle 4 refined linguistic consistency, mobile responsiveness, content transparency, and scientific accuracy, emphasizing explicit instructional guidance and bilingual accessibility. Conclusions: Our iterative process produced a personalized, bilingual digital decision aid to support evidence-informed, values-congruent decisions about COVID-19 vaccination. A randomized controlled trial will further evaluate VaxDA-C19’s impact on vaccination intentions, knowledge retention, emotional responses, decisional conflict, and decisional regret. If it proves effective, the patient decision aid may also be used as a platform to support other vaccine decisions, namely, influenza, measles, shingles, pertussis, and potentially other emerging infectious diseases.

  • Open Access

    Organizing pneumonia potentially caused by infliximab in a pediatric patient with ulcerative colitis

    by Brian Lee, Isaac Martin, Kevin Bax, Samira Jeimy

    Background: Organizing pneumonia (OP) is a rare interstitial lung disease characterized by intra-alveolar fibroblastic plugs and chronic inflammation. Although most cases are idiopathic, OP may occur secondary to infections, autoimmune disease, or drug exposure. Pulmonary complications of tumor necrosis factor-alpha (TNF-α) inhibitors are uncommon, and infliximab-associated OP has not yet been described in the pediatric population. Case presentation: A 12-year-old girl with ulcerative colitis (UC) on infliximab presented with three weeks of dyspnea, fever, and pleuritic chest pain. Computed tomography (CT) revealed bilateral peripheral infiltrates. Microbiologic testing and bronchoalveolar lavage were negative. Wedge biopsy demonstrated fibroblastic plugs (Masson bodies), consistent with OP. Infliximab was discontinued. The patient’s symptoms improved without corticosteroids, with near-complete radiologic resolution at 2 months. Conclusions: This case highlights probable infliximab-associated OP in a pediatric patient, highlighting a need for awareness of rare pulmonary toxicities from biologics. Importantly, resolution occurred without corticosteroids, suggesting that withdrawal of the offending agent may suffice in select cases.


  • Open Access

    Frey’s syndrome in an infant misdiagnosed as food allergy

    by Melanie Semaan, Sheikha Alkhuder, Samira Jeimy

    Background: Frey’s syndrome (auriculotemporal syndrome) is characterized by gustatory flushing and sweating in the distribution of the auriculotemporal nerve. Although classically described after parotid surgery in adults, congenital and idiopathic forms are increasingly recognized in infants. Because symptoms occur during feeding, the condition can closely mimic IgE-mediated food allergy, leading to unnecessary dietary restrictions and anxiety. Case presentation: We report an 8-month-old boy referred for evaluation of suspected multiple food allergies after several emergency department visits for feeding-associated facial redness, interpreted by caregivers as “hives”, and accompanied by significant parental anxiety and progressive dietary avoidance. On detailed reassessment, reactions were found to consist of localized, unilateral flushing and sweating of the right cheek, without urticaria or systemic features. Skin prick testing and serum-specific IgE testing to common food allergens were negative. During a supervised baked milk oral food challenge, a similar unilateral cutaneous reaction was observed, confirming the diagnosis of Frey’s syndrome. A home-recorded video demonstrated comparable findings during feeding with formula. Discussion: Frey’s syndrome is an important and under-recognized mimic of food allergy in infancy. Careful attention to laterality, absence of systemic involvement, and reproducibility across foods can prevent misdiagnosis, reduce unnecessary dietary restriction, and alleviate family anxiety. Conclusion: Frey’s syndrome should be considered in infants with reproducible unilateral flushing during feeding. Awareness among allergists can prevent misdiagnosis, reduce unnecessary food avoidance, and support safe nutritional and developmental outcomes.

  • Top Cited Papers
    Open Access

    The International/Canadian hereditary angioedema guideline

    by Stephen Betschel, Karen Binkley, Rozita Borici-Mazi, Hugo Chapdelaine, Jacques Hébert, Amin Kanani, Paul K. Keith, Gina Lacuesta, Susan Waserman, William Yang, et al.

    This update to the 2019 Canadian Hereditary Angioedema (HAE) Guideline broadens its focus to include the management of patients with HAE worldwide, building on its established international framework. It has been developed through a collaboration of Canadian and international HAE experts and patient groups, coordinated by the Canadian Hereditary Angioedema Network. The objective is to provide evidence-based recommendations, using the Grading of Recommendations Assessment, Development and Evaluation system, for the management of patients with HAE. These include recommendations for the treatment of attacks, short-term prophylaxis, and long-term prophylaxis, as well as recommendations for self-administration, individualized therapy, health-related quality of life, and comprehensive care. New to the 2024 edition are specific recommendations for the treatment of angioedema attacks in individuals with HAE who are breastfeeding/lactating, as well as a dedicated section on shared decision-making. HAE results in spontaneous and often unpredictable attacks of painful swelling, typically affecting the extremities, bowel mucosa, genitals, face, and upper airway. These attacks are associated with significant functional impairment, reduced health-related quality of life, and in the case of laryngeal attacks, a high risk of mortality. Managing HAE is complex, and patient care in Canada, similar to many other countries, remains inconsistent and suboptimal. Care delivery lags behind nations that have implemented more structured management models for HAE, and offer broader access to a wider range of approved therapies. This guideline is intended to be used to optimize HAE management, highlight the importance of individualized care, and provide guidance to healthcare providers, policymakers, patients, and advocates. Primary target users include healthcare providers who are managing patients with HAE, as well as emergency and intensive care physicians, primary care physicians, gastroenterologists, dentists, otolaryngologists, pediatricians, hematologists, dermatologists, and gynecologists who will encounter patients with HAE and need to be aware of this condition. Hospital administrators, insurers and policy makers may also find this guideline helpful.